Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04162496 · ClinicalTrials.gov registry record · NA

Restylane Refyne for Correction of Horizontal Neck Rhytides

A NA study of Aging and Wrinkle, sponsored by Siperstein Dermatology.

Active
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT04162496: Active NA study of Aging and Wrinkle, sponsored by Siperstein Dermatology.

NCT04162496 is a NA study of Aging and Wrinkle that is active but no longer recruiting, run by Siperstein Dermatology. The registered enrollment target is 24 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04162496, a NA study of Aging and Wrinkle, is active but no longer recruiting, sponsored by Siperstein Dermatology.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Subjects with grades ranging from 1---3 on the Transverse Neck Line Scale, will be randomized to receive up to 1cc of Restylane Refyne on one side of their neck utilizing a cannula and up to 1cc of Restylane Refyne on the other side utilizing a 30--gauge needle. On Day 30, this treatment with the same left---right assignment can be repeated if optimal correction on either side has not been achieved according to the treating investigator. Subjects will return 24--48 hours after their first treatment, to fill out questionnaires, take pictures, and to be assessed by blinded evaluators regarding adverse events. Subjects will also return 30 days after their final treatment to fill out final questionnaires, take pictures, and to be assessed by blinded evaluators regarding improvement of static rhytides.

Primary Outcome

Difference in the mean absolute change from baseline on a 5--point validated transverse neck line scale. The lowest score 0 signifies no line and a better outcome while the highest score 4 signifies a worse outcome.

Interventions

  • DEVICE Restylane Refyne

Study Locations (1)

Florida

  • Siperstein Dermatology - Boynton Beach

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2020-08-11
Est. Completion 2021-09-30
Phase NA
Siperstein Dermatology

3 total trials

What the registry record for NCT04162496 still lists

NCT04162496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which Restylane Refyne is the first listed.

NCT04162496 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04162496 about?

NCT04162496 is a clinical study titled "Restylane Refyne for Correction of Horizontal Neck Rhytides". Subjects with grades ranging from 1---3 on the Transverse Neck Line Scale, will be randomized to receive up to 1cc of Restylane Refyne on one side of their neck utilizing a cannula and up to 1cc of Restylane Refyne on the other side utilizing a 30--gauge needle. On Day 30, this treatment with the sa...

What is the current status of trial NCT04162496?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2020-08-11. Estimated completion is 2021-09-30.

What conditions does trial NCT04162496 study?

This clinical trial studies the following conditions: Aging, Wrinkle, Rhytides.

What interventions are being tested in trial NCT04162496?

The interventions under investigation include: Restylane Refyne (DEVICE).

Who is sponsoring clinical trial NCT04162496?

This trial is sponsored by Siperstein Dermatology, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04162496 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04162496's enrollment target sits among peer trials

24 214th of 262 higher than 40 of 262 other Aging trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04162496, the US trial registry maintained by the National Library of Medicine. NCT04162496 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.